West Pharmaceutical Services (NYSE:WST) updated its FY 2020
Pre-Market earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 3.45-3.55 for the period, compared to the Thomson Reuters consensus estimate of $3.46. The company issued revenue guidance of $1.95-1.97 billion, compared to the consensus revenue estimate of $1.95 billion.West Pharmaceutical Services also updated its FY20 guidance to $3.45-3.55 EPS.
Several research firms recently weighed in on WST. Bank of America lowered West Pharmaceutical Services from a neutral rating to an underperform rating and set a $135.00 target price for the company. in a report on Thursday, December 12th. Zacks Investment Research lowered West Pharmaceutical Services from a buy rating to a hold rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $132.29.
Shares of WST stock traded up $0.19 during trading hours on Friday, reaching $174.57. 391,947 shares of the company’s stock were exchanged, compared to its average volume of 418,727. West Pharmaceutical Services has a fifty-two week low of $100.93 and a fifty-two week high of $175.21. The stock has a market capitalization of $11.84 billion, a P/E ratio of 57.24, a P/E/G ratio of 3.31 and a beta of 1.21. The business has a fifty day moving average price of $156.35 and a 200-day moving average price of $147.47. The company has a quick ratio of 2.31, a current ratio of 3.00 and a debt-to-equity ratio of 0.17.
West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.10. West Pharmaceutical Services had a return on equity of 16.66% and a net margin of 12.82%. The company had revenue of $470.60 million during the quarter, compared to analyst estimates of $451.53 million. During the same period in the previous year, the company earned $0.73 earnings per share. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. As a group, research analysts expect that West Pharmaceutical Services will post 3.14 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 5th. Stockholders of record on Wednesday, January 22nd were issued a dividend of $0.16 per share. The ex-dividend date was Tuesday, January 21st. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.15. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.37%. West Pharmaceutical Services’s payout ratio is 22.78%.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading: Dividend Aristocrat Index
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.